BEX2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09991(BEX2 Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P09991(BEX2 Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

**Background of BEX2 Antibody**

BEX2 (Brain Expressed X-linked 2) is a member of the BEX/TAX1BP3 family, which comprises small, evolutionarily conserved proteins predominantly expressed in the nervous system. Initially identified for its role in neuronal development and differentiation, BEX2 has gained attention for its dual functions in both normal physiology and disease, particularly cancer. It interacts with key signaling pathways, including p53. NF-κB, and receptor tyrosine kinases, modulating processes like apoptosis, proliferation, and transcriptional regulation.

In cancer research, BEX2 exhibits context-dependent roles, acting as a tumor suppressor or oncogene. For instance, it is downregulated in glioblastoma, where its loss correlates with poor prognosis, while overexpression in breast or pancreatic cancers may drive tumor progression. This duality underscores its complex regulatory mechanisms and tissue-specific interactions.

BEX2 antibodies are essential tools for studying its expression, localization, and functional roles. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in the exploration of BEX2's involvement in diseases. Recent studies also highlight its potential as a therapeutic target or biomarker, particularly in cancers with dysregulated neurodevelopmental pathways. However, challenges remain in fully elucidating its molecular partners and signaling cross-talk, necessitating further research to harness its clinical relevance.